找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Direct Oral Anticoagulants; From Pharmacology to Riccardo Proietti,Ahmed AlTurki,T. Jared Bunch Book 2021 Springer Nature Switzerland AG 20

[复制链接]
楼主: FAD
发表于 2025-3-25 05:24:40 | 显示全部楼层
https://doi.org/10.1007/978-981-32-9127-0thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of venous thromboembolism (VTE). In patients with multiple conditions, as in particular NVAF ones or with cancer, the contemporary administration of several drugs can cause relevant drug–
发表于 2025-3-25 08:35:18 | 显示全部楼层
The Community Street Soccer Programr Xa inhibitors (rivaroxaban, apixaban, edoxaban, betrixaban). They have largely replaced vitamin K anticoagulants (VKAs) in clinical practice. Their overall safety profile concerning bleeding appears to be at least equivalent, if not superior, to VKAs. However, the lack of a specific reversal agent
发表于 2025-3-25 12:01:28 | 显示全部楼层
https://doi.org/10.1007/978-1-4614-5996-5ant agents play a key role in preventing this complication. Through years, several risk stratification algorithms have been investigated, while others are still object of debate. According to current guidelines, CHA2DS2VASc score and HAS-BLED score are the ones suggested for stroke and bleeding risk
发表于 2025-3-25 16:29:23 | 显示全部楼层
William J. Moreau,Dustin Nabhanmorrhagic events are increased in patients with kidney disease. Oral anticoagulation therapy, nowadays preferably with direct oral anticoagulants (DOACs), represents the cornerstone for ischemic stroke prevention in high-risk patients. However, all four available DOACs (dabigatran, apixaban, rivarox
发表于 2025-3-25 22:12:35 | 显示全部楼层
发表于 2025-3-26 03:46:07 | 显示全部楼层
Brenden J. Balcik,Aaron J. Monseauovascular (CV) risk, more and more evidences suggest a favorable prognosis in obese subjects with cardiovascular disease (CVD), a phenomenon known as “obesity paradox.” Obesity paradox has been demonstrated in various CVD including atrial fibrillation (AF) and venous thromboembolism (VTE) for which
发表于 2025-3-26 06:57:18 | 显示全部楼层
https://doi.org/10.1007/978-3-030-36790-9thromboembolism is a leading cause of mortality, especially in patients undergoing chemotherapy. The anticoagulant strategy to be administered in these cases is particularly difficult to choose due to an altered state of coagulation that makes the balance between hypercoagulation and bleeding risk i
发表于 2025-3-26 12:02:28 | 显示全部楼层
发表于 2025-3-26 14:24:55 | 显示全部楼层
发表于 2025-3-26 18:58:51 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-6 01:35
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表